2. Anti-infection Stem Cell/Wnt PI3K/Akt/mTOR Cell Cycle/DNA Damage Epigenetics
  3. Antibiotic GSK-3 Bacterial Aurora Kinase
  4. Ceftriaxone sodium salt

Ceftriaxone sodium salt  (Synonyms: Ro 13-9904)

Cat. No.: HY-B0712B Purity: 99.25%
COA Handling Instructions

Molarity Calculator

Ceftriaxone sodium salt (Ro 13-9904) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone sodium salt is a covalent inhibitor of GSK3β with IC50 value of 0.78 μM. Ceftriaxone sodium salt is an inhibitor of Aurora B. Ceftriaxone sodium salt has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone sodium salt can be used in the study of bacterial infections and meningitis.

For research use only. We do not sell to patients.

Ceftriaxone sodium salt Chemical Structure

Ceftriaxone sodium salt Chemical Structure

CAS No. : 74578-69-1

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
100 mg USD 60 In-stock
500 mg USD 108 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

Other Forms of Ceftriaxone sodium salt:

Ceftriaxone sodium salt Related Antibodies

Top Publications Citing Use of Products

View All Antibiotic Isoform Specific Products:

View All Isoforms
Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

View All GSK-3 Isoform Specific Products:

View All Isoforms
GSK-3 GSK-3α GSK-3β

View All Aurora Kinase Isoform Specific Products:

View All Isoforms
Aurora Kinase Aurora A Aurora B Aurora C

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Ceftriaxone sodium salt (Ro 13-9904) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone sodium salt is a covalent inhibitor of GSK3β with IC50 value of 0.78 μM. Ceftriaxone sodium salt is an inhibitor of Aurora B. Ceftriaxone sodium salt has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone sodium salt can be used in the study of bacterial infections and meningitis[1][2][3][4][5][6][7].

IC50 & Target

β-lactam

 

In Vitro

Ceftriaxone sodium salt (100 μM, 24 h) protects MPP+ treated astrocytes by inhibiting the NF-κB/JNK/c-Jun signaling pathway [3].
Ceftriaxone sodium salt (500 μM, 24-48 h) effectively inhibits unanchored cell growth in A549, H520 and H1650 lung cancer cells by inhibiting Aurora B[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ceftriaxone sodium salt Related Antibodies

Cell Viability Assay[3]

Cell Line: Astrocyte
Concentration: 100 μM
Incubation Time: 24 h
Result: Improved cell viability and increased glutamate uptake after MPP+ expose.

Western Blot Analysis[3]

Cell Line: Astrocyte
Concentration: 100 μM
Incubation Time: 24 h
Result: Enhanced GLT-1 and GFAP expression.
Decreased the expression of p-p50、p-IKKα、p-Relb.
Decreased the number of TUNEL-positive cells.
In Vivo

Ceftriaxone sodium salt (200 mg/kg Intraperitoneal injection for 6 weeks) improves functional markers and oxidative stress and inflammation parameters in a rat model of D-galactose (DGL) -induced liver and kidney injury[5].
Ceftriaxone sodium salt (200, 400 mg/kg, Intraperitoneal injection) has a protective effect on convulsion induced by Pentylenetetrazol (PTZ) and PTZ-related oxidative damage in rats[6].
Ceftriaxone sodium salt (100, 200 mg/kg, Intraperitoneal injection) reduces mechanical dysodynia and hyperalgesia by activating GLT-1 in streptozotocin (HY-13753)-induced diabetic rat models[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: DGL-induced rat model[5]
Dosage: 200 mg/kg
Administration: i.p.
Result: Reduced the BUN、Cr 、AST and ALT levels.
Attenuated the MDA levels and enhanced GPx and CAT activities.
Reduced the levels of IL-1β and TNF-α mRNA.
Animal Model: PTZ-induced rat model[6]
Dosage: 200, 400 mg/kg
Administration: i.p. 60 min before to PTZ (70 mg/kg)
Result: Both of the two ceftriaxone groups had lower spike percentages than the saline group.
Significantly lower MDA levels and higher SOD activity in 200 and 400 mg/kg.
Clinical Trial
Molecular Weight

598.54

Formula

C18H16N8Na2O7S3
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C(O[Na])C(N12)=C(CSC(N(C)N=C3O[Na])=NC3=O)CS[C@]2([H])[C@H](NC(/C(C4=CSC(N)=N4)=N\OC)=O)C1=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light)

Solvent & Solubility
In Vitro: 

DMSO : 50 mg/mL (83.54 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : ≥ 40 mg/mL (66.83 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.6707 mL 8.3537 mL 16.7073 mL
5 mM 0.3341 mL 1.6707 mL 3.3415 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (4.18 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (4.18 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 100 mg/mL (167.07 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 1.6707 mL 8.3537 mL 16.7073 mL 41.7683 mL
5 mM 0.3341 mL 1.6707 mL 3.3415 mL 8.3537 mL
10 mM 0.1671 mL 0.8354 mL 1.6707 mL 4.1768 mL
15 mM 0.1114 mL 0.5569 mL 1.1138 mL 2.7846 mL
20 mM 0.0835 mL 0.4177 mL 0.8354 mL 2.0884 mL
25 mM 0.0668 mL 0.3341 mL 0.6683 mL 1.6707 mL
30 mM 0.0557 mL 0.2785 mL 0.5569 mL 1.3923 mL
40 mM 0.0418 mL 0.2088 mL 0.4177 mL 1.0442 mL
50 mM 0.0334 mL 0.1671 mL 0.3341 mL 0.8354 mL
60 mM 0.0278 mL 0.1392 mL 0.2785 mL 0.6961 mL
DMSO 80 mM 0.0209 mL 0.1044 mL 0.2088 mL 0.5221 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Ceftriaxone sodium salt Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Ceftriaxone74578-69-1Ro 13-9904AntibioticGSK-3BacterialAurora KinaseGlycogen synthase kinase-3Glycogen synthase kinase 3GSK3βAurora BAstrocyteA549DGL-induced rat modelPTZ-induced rat modelantibacterialInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Ceftriaxone sodium salt
Cat. No.:
HY-B0712B
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.